nach oben

Acta Diabetologica

Erschienen in:

25.02.2017 | Original Article

Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial

verfasst von: S. Bo, V. Ponzo, A. Evangelista, G. Ciccone, I. Goitre, F. Saba, M. Procopio, M. Cassader, R. Gambino

Erschienen in: Acta Diabetologica | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Aims

The anti-inflammatory effects of the polyphenol resveratrol in patients with type 2 diabetes mellitus (T2DM) are controversial. Its role on pentraxin 3 (PTX3) concentrations, a human acute phase protein, has never been evaluated. Our aim was to determine whether a two-dosage resveratrol supplementation (500 and 40 mg/day) has an impact on PTX3 values in T2DM patients from a double-blind randomized placebo-controlled trial. Variations in total antioxidant status (TAS) were evaluated too.

Methods

A total of 192 T2DM patients were randomized to receive resveratrol 500 mg/day (Resv 500 arm), resveratrol 40 mg/day (Resv 40 arm) or placebo for 6 months. At baseline and at the trial end, PTX3 and TAS values were determined.

Results

A dose-dependent increase in PTX3 concentrations of 4.7% (Resv 40 arm) and 26.3% (Resv 500 arm), and 8.0% reduction after placebo were found. Adjusted mean differences of change versus placebo were 0.16 (95% CI 0.01–0.32) and 0.25 (0.09–0.42) in the Resv 40 and Resv 500 arms, respectively. At subgroup analyses, lower diabetes duration, aspirin, alcohol use, younger age, female gender, smoking (Resv 500 arm) and female gender and aspirin use (Resv 40 arm) were associated with higher PTX3 increments. A dose-dependent increment in TAS values in the resveratrol arms (1.4 and 6.4% for Resv 40 and Resv 500, respectively), and a reduction in placebo arm (−8.9%) were observed. Adjusted mean differences of change were 28.5 (95% CI 10.1–46.8) and 44.8 (25.4–64.1) in the Resv 40 and Resv 500 arms, respectively.

Conclusion

Resveratrol supplementation increased PTX3 and TAS levels in a dose-dependent manner in T2DM patients. At present, potential clinical implications of these results remain unclear.

ClinicalTrials.gov Identifier

NCT02244879.

Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomás-Barberán FA, García-Conesa MA, Espín JC (2013) Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharmac Des 19:6064–6093CrossRef

Ponzo V, Soldati L, Bo S (2014) Resveratrol: a supplementation for men or for mice? J Transl Med 12:158CrossRefPubMedPubMedCentral

Novelle MG, Wahl D, Diéguez C, Bernier M, de Cabo R (2015) Resveratrol supplementation: where are we now and where should we go? Ageing Res Rev 21:1–15CrossRefPubMed

Visioli F (2014) The resveratrol fiasco. Pharmacol Res 90:87CrossRefPubMed

Bo S, Ciccone G, Castiglione A et al (2012) Antiinflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers. Curr Med Chem 20:1323–1331CrossRef

Fujitaka K, Otani H, Jo F et al (2011) Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res 31:842–847CrossRefPubMed

Poulsen MM, Vestergaard PF, Clasen BF et al (2013) High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62:1186–1195CrossRefPubMedPubMedCentral

Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI (2013) Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 29:178–183CrossRefPubMed

Ghanim H, Sia CL, Abuaysheh S et al (2010) An antiinflammatory and reactive oxygen species suppressive effects of an extract of polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 95:E1–E8CrossRefPubMedPubMedCentral

10.

Timmers S, Konings E, Bilet L et al (2011) Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14:612–622CrossRefPubMed

11.

Tomé-Carneiro J, Gonzálvez M, Larrosa M et al (2012) One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 110:356–363CrossRefPubMed

12.

Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ et al (2013) One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res 72:69–82CrossRefPubMed

13.

van der Made SM, Plat J, Mensink RP (2015) Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS one 10:e0118393CrossRefPubMedPubMedCentral

14.

Bo S, Ponzo V, Ciccone G et al (2016) Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol Res 111:896–905CrossRefPubMed

15.

Vilahur G, Badimon L (2015) Biological actions of pentraxins. Vasc Pharmacol 73:38–44CrossRef

16.

Norata CD, Marchesi P, Pirillo A et al (2008) Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 28:925–931CrossRefPubMed

17.

Foo SS, Reading PC, Jaillon S, Mantovani A, Mahalingam S (2015) Pentraxins and collectins: friend or foe during pathogen invasion? Trends Microbiol 23:799–811CrossRefPubMed

18.

Fornai F, Carrizzo A, Ferrucci M et al (2015) Brain diseases and tumorigenesis: the good and bad cops of pentraxin 3. Int J Biochem Cell Biol 69:70–74CrossRefPubMed

19.

Daigo K, Mantovani A, Bottazzi B (2014) The yin-yang of long PTX3 in inflammation and immunity. Immunol Lett 161:38–43CrossRefPubMed

20.

Witasp A, Rydén M, Carrero JJ et al (2013) Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS one 8:e63493CrossRefPubMedPubMedCentral

21.

Yasunaga T, Ikeda S, Koga S et al (2014) Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein. Int Heart J 55:160–164CrossRefPubMed

22.

Carrizzo A, Lenzi P, Procaccini C et al (2015) Pentraxin 3 induces vascular endothelial dysfunction through a p-selectin/matrix metalloproteinase-1 pathway. Circulation 131:1495–1505CrossRefPubMed

23.

Liu S, Qu X, Liu F, Wang C (2014) Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection. Med Inflammat ID 421429

24.

Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM (2009) Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 29:594–599CrossRefPubMedPubMedCentral

25.

Latini R, Maggioni AP, Peri G et al (2004) Lipid assessment trial italian network (LATIN) investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110:2349–2354CrossRefPubMed

26.

Salio M, Chimenti S, De Angelis N et al (2008) Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 117:1055–1064CrossRefPubMed

27.

Rodriguez-Grande Swana M, Nguyen L, Englezou P et al (2014) The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury. J Cereb Blood Flow Metab 34:480–488CrossRefPubMed

28.

Ravizza T, Moneta D, Bottazzi B et al (2001) Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. Neuroscience 105:43–53CrossRefPubMed

29.

Bottazzi B, Inforzato A, Messa M et al (2016) The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodeling. J Hepatol 64:1416–1427CrossRefPubMed

30.

Ogawa T, Kawano Y, Imamura T et al (2010) Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity 18:1871–1874CrossRefPubMed

31.

Barazzoni R, Aleksova A, Carriere C et al (2013) Obesity and high waist circumference are associated with low circulating pentraxin 3 in acute coronary syndrome. Cardiovasc Diabetol 12:167CrossRefPubMedPubMedCentral

32.

Witasp A, Carrero JJ, Michaëlsson K et al (2014) Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. Obesity 22:1373–1379CrossRefPubMed

33.

Miyazaki T, Chiuve S, Sacks FM, Ridker PM, Libby P, Aikawa M (2014) Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE Trial. PLoS one 9:e94073CrossRefPubMedPubMedCentral

34.

Osorío-Conles O, Guitart M, Chacón MR et al (2011) Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab 301:E1254–E1261CrossRefPubMed

35.

Barazzoni R, Palmisano S, Gortan Cappellari G et al (2016) Gastric bypass—induced weight loss alters obesity-associated patterns of plasma pentraxin-3 and systemic inflammatory markers. Surg Obes Relat Dis 12:23–32CrossRefPubMed

36.

Santilli F, Guagnano MT, Innocenti P et al (2016) Pentraxin 3 and platelet activation in obese patients after gastric banding. Circ J 80:502–511CrossRefPubMed

37.

Nakamura A (2015) Is pentraxin 3 a biomarker, a player, or both in the context of coronary atherosclerosis and metabolic factors? Heart Vessels 30:752–761CrossRefPubMed

38.

Yilmaz MI, Axelsson J, Sonmez A et al (2009) Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 4:535–541CrossRefPubMedPubMedCentral

39.

Yang HS, Woo JE, Lee SJ, Park SH, Woo JM (2014) Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in korean patients with type 2 diabetes mellitus. Investig Ophthalmol Vis Sci 55:5989–5997CrossRef

40.

Salcini C, Atasever-Arslan B, Sunter G et al (2016) High plasma pentraxin 3 levels in diabetic polyneuropathy patients with nociceptive pain. Tohoku J Exp Med 239:73–79CrossRefPubMed

41.

Wang R, Zhang J, Hu W (2016) Association of serum pentraxin 3 concentrations with diabetic nephropathy. J Investig Med 64:1124–1127CrossRefPubMed

42.

Seman NA, Abu Seman N, Witasp A et al (2013) Evolution of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population. J Diabetes Res ID 298019

43.

Sun H, Tian J, Xian W, Xie T, Yang X (2015) Pentraxin 3 attenuates renal damage in diabetic nephropathy by promoting M2 macrophage differentiation. Inflammation 38:1739–1747CrossRefPubMed

44.

Bonavita E, Gentile S, Rubino M et al (2015) PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 160:700–714CrossRefPubMed

45.

Klouche M, Peri G, Knabbe C et al (2004) Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175:221–228CrossRefPubMed

46.

Suzuki D, Toyoda M, Kimura M et al (2013) Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. Intern Med 52:1029–1034CrossRefPubMed

47.

Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP (2013) Diabetes mellitus and inflammation. Curr Diabetes Rep 13:435–444CrossRef

48.

Jaillon S, Peri G, Delneste Y et al (2007) The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 204:793–804CrossRefPubMedPubMedCentral

49.

Whiting PH, Kalansooriya A, Holbrook I, Haddad F, Jennings PE (2008) The relationship between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus. Br J Biomed Sci 65:71–74CrossRefPubMed

50.

Chang YC, Chuang LM (2010) The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res 2:316–331PubMedPubMedCentral

51.

Crujeiras AB, Díaz-Lagares A, Carreira MC, Amil M, Casanueva FF (2013) Oxidative stress associated to dysfunctional adipose tissue: a potential link between obesity, type 2 diabetes mellitus and breast cancer. Free Rad Res 47:243–256CrossRef

52.

Bode LM, Bunzel D, Huch M et al (2013) In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr 97:295–309CrossRefPubMed

Titel: Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial
verfasst von: S. Bo
V. Ponzo
A. Evangelista
G. Ciccone
I. Goitre
F. Saba
M. Procopio
M. Cassader
R. Gambino
Publikationsdatum: 25.02.2017
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 5/2017
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-017-0977-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial

Abstract

Aims

Methods

Results

Conclusion

ClinicalTrials.gov Identifier

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Aims

Methods

Results

Conclusion

ClinicalTrials.gov Identifier

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes

Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus

Treatment of diabetic gastroparesis with botulinum toxin injection guided by endoscopic ultrasound in a patient with type 1 diabetes: the first report

Investigation of the relationship between hemoglobin and serum iron levels and early-phase insulin secretion in non-diabetic subjects: statistical and methodological issues

Association between type 2 diabetes and cancer incidence in Taiwan: data from a prospective community-based cohort study

Retinal neurodegeneration in patients with type 1 diabetes mellitus: the role of glycemic variability

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin